RT @ericdeinmd: Year in Review #ACR22 IVIG received FDA approval for adult dermatomyositis, shows benefit versus placebo
Tweet Content
Year in Review #ACR22
IVIG received FDA approval for adult dermatomyositis, shows benefit versus placebo
First approved Rx for inflammatory myositis
@RheumNow https://t.co/T6qVTQQdTp
Show on Archive Page
On
Display in Search Results
On
PDQ
Off